Treprostinil
- Generic Name
- Treprostinil
- Brand Names
- Orenitram, Remodulin, Tyvaso, Trepulmix
- Drug Type
- Small Molecule
- Chemical Formula
- C23H34O5
- CAS Number
- 81846-19-7
- Unique Ingredient Identifier
- RUM6K67ESG
- Background
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation. It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. The first agent approved for th...
- Indication
The FDA has indicated treprostinil for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability. It is also used to treat pulmonary arterial hypertension in patients requiring transition from epoprostenol. The Health Canada label specifies that treprostinil is indicated ...
- Associated Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
- Associated Therapies
- -
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
- Conditions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Excelsior
- Target Recruit Count
- 20
- Registration Number
- NCT06603285
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT05564637
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT05067270
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇩🇪Profil Mainz, Mainz, Germany
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT04675944
- Locations
- 🇩🇪
PAREXEL International - Early Phase Clinical Unit, Berlin, Germany
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04005469
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
- Conditions
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 43
- Registration Number
- NCT03888365
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Beverly Hills, California, United States
🇺🇸The Mount Sinai Hospital, New York, New York, United States
🇺🇸Pulmonary Health Physicians, PC, Fayetteville, New York, United States
Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Magdi H. Yacoub
- Target Recruit Count
- 30
- Registration Number
- NCT03835676
- Locations
- 🇪🇬
Aswan Heart Centre - Magdi Yacoub Heart Foundation, Aswan, Egypt
Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT02865733
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT02847260
A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT02770521
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.